undamentalytics Newsletter

Anika Therapeutics, Inc. cash flow statement

In fiscal 2025, Anika Therapeutics, Inc.'s operations generated $11.2m of cash; it spent $6.8m on capital projects, leaving free cash flow of $4.4m. It returned $9.5m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Anika Therapeutics, Inc.: cash flow statement, annual
Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations381011254040244135371384−25116
Depreciation and amortisation134555444656676756
Stock-based pay1111122361165111415131013
Capital spending4312029149532575875
Free cash flow−159925383110323034113−3−7−241
Free cash flow after stock pay−248823372872619286−8−17−22−15−6−13
Share buybacks———————25—3030000511915

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ANIK vs OMANIK vs OWLTANIK vs BBNXANIK vs RXST

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Anika Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anika Therapeutics, Inc.